Stephen P. Hunger, MD

Associate Director (Pediatric Cancer Research), Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine

Chief, Division of Pediatric Oncology

Director, Center for Childhood Cancer Research

Jeffrey E. Perelman Distinguished Chair in the Department of Pediatrics

Professor, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania

2023, Fellow of the American Society of Clinical Oncology
2022, 33rd Ben Abelson Memorial Visiting Professor, Washington University School of Medicine and St. Louis Children’s Hospital
2022, William E. Hathaway Distinguished Visiting Professor, University of Colorado, Section of Pediatric Hematology/Oncology/BMT
2020, Karen Meltzer Lecture; Princess Margaret Cancer Centre
2018, George R. Buchanan Lectureship Award, American Society of Pediatric, Hematology/Oncology Annual Meeting
2018, Invited Luminary Speaker, American Society of Pediatric Hematology/Oncology, Annual Meeting
2017, Visiting Professor, King Abdulaziz Medical City, Ministry of National Guard—Health Affairs, Jeddah, Saudi Arabia
2017, 15th Annual Evan T. J. Dunbar Lectureship, University of Louisville
2017, 17th Annual Alexander Koufus Memorial Lecture; Akron Children’s Hospital
2015-present, Jeffrey E. Perelman Distinguished Chair in the Department of Pediatrics, Children's Hospital of Philadelphia
2015, Elected to the John Morgan Society of the University of Pennsylvania
2014, Ann T. Bass Endowed Visiting Professor, Stanford University, Stanford CA
2013, Visiting Professor, McMaster University, Hamilton, Ontario, Canada
2012, First Annual Sam Gross Visiting Professor in Pediatric Oncology, University of Florida College of Medicine, Gainesville FL
2011, Visiting Professor, University of Chicago, Chicago, IL
2011-present, Cambridge Who’s Who Executive and Professional Registry
2009, SIOP Award for Basic Science Abstract
2009-present, Guide to America’s Top Oncologists
2007-present, Ergen Family Chair in Pediatric Cancer
2004-present, Guide to America’s Top Physicians
2002-present, The Best Doctors In America
2001-2007, STOP! Children’s Cancer Endowed Chair in Pediatric Oncology
1998-2001, Leukemia Society of America Translational Research Awardee
1997-1999, Professional Development Award, The Children’s Hospital Research Institute, Denver, CO
1995-1997, 1995-1997 BLOOD/American Society of Hematology (ASH) Scholar Award
1992-1994, Individual National Research Service Award, National Cancer Institute
1991-1992, American Cancer Society Physician's Research Training Award
1982, Linda Ives Memorial Fund Award for Research in Pediatrics, University of Connecticut School of Medicine
1978, Undergraduate Research Opportunities Award, Massachusetts Institute of Technology
1977-1981, National Merit Scholar

American Association for the Advancement of Science
American Society of Clinical Oncology
American Society of Hematology
American Society of Microbiology
American Society of Pediatric Hematology-Oncology
Children’s Oncology Group
 - 2022-present, COG AALL2131 Study Committee: A Randomized International Phase 3 Trial of Imatinib and Chemotherapy with or without Blinatumomab (IND#: NCI, NSC#: 765986) in Patients with Newly-Diagnosed B-Acute Lymphoblastic Leukemia Harboring ABL-Class Fusions
 - 2016-present, Vice Chair, COG AALL1631 Study Committee: International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
 - 2013-present, COG AALL1331 Study Committee: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
 - 2013-present, COG AALL1231 Study Committee: Phase III Randomized Trial Investigating Bortezomib (PS-341, Velcade) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LL)
 - 2011-present, Co-Chair, COG AALL1122 Bristol Myers Squibb (BMS) Clinical Protocol CA180-72]
 - 2010-present, COG AALL1131 Study Committee: Treatment of Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia ALL
 - 2010-present, COG ACCL1033 Study Committee: A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
 - 2009-present, COG AALL0932 Study Committee: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
 - 2005-present, AALL0434 Study Committee: ntensified Methotrexate, Nelarabine (Compound 506U78; IND # 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia
 - 2000-present, ALL Disease Committee
 - 1999-present, 1991 Study Committee: Escalating intravenous vs. oral methotrexate and single vs. double delayed intensification therapy for standard risk acute lymphoblastic leukemia
International Society of Paediatric Oncology (member #860)
Society for Pediatric Research

Editorial positions

2015-present, Grant Reviewer; The V Foundation for Cancer Research Pediatric Cancer Research Awards
2009-present, St. Baldrick’s Foundation Grant Review Committee
2006-present, Alex’s Lemonade Stand Foundation Grant Review Committee

Ad Hoc Reviewer

1994-present, Blood
1994-present, Leukemia
1994-present, Genes
1994-present, Chromosomes & Cancer
1994-present, Molecular and Cellular Biology
1994-present, Proc Natl Acad Sci USA
1994-present, Journal of Pediatric Hematology/Oncology
1994-present, Hematologica
1994-present, Bone Marrow Transplantation
1994-present, Journal of Clinical Oncology
1994-present, Pediatric Blood and Cancer

Academic and institutional committees

2009-2013, St. Baldrick’s Foundation Grant Review Committee
2006-2013, Alex’s Lemonade Stand Grant Review Committee
2000-present, Children’s Oncology Group grant and research proposal reviews

Acute lymphoblastic leukemia (ALL)